Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amicus Therapeutics, Inc. - Common Stock
(NQ:
FOLD
)
14.27
+0.03 (+0.21%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amicus Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
Today 14:27 EST
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...
Via
MarketMinute
Topics
Economy
Intellectual Property
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
December 29, 2025
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...
Via
MarketMinute
Topics
ETFs
Intellectual Property
Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal
↗
December 19, 2025
Via
Stocktwits
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Earnings Scheduled For July 31, 2025
↗
July 31, 2025
Via
Benzinga
Earnings Scheduled For May 1, 2025
↗
May 01, 2025
Via
Benzinga
Amicus Therapeutics Earnings Preview
↗
April 30, 2025
Via
Benzinga
The Liquidity Vacuum: Thin Holiday Trading Sparks Volatility as 2025 Draws to a Close
December 26, 2025
As the final week of 2025 unfolds, the hallowed halls of the New York Stock Exchange and the digital corridors of the Nasdaq have transformed into a "ghost town." With many institutional traders having...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Unusual volume stocks in Tuesday's session
↗
December 23, 2025
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via
Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
December 19, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Earnings Scheduled For February 19, 2025
↗
February 19, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts
↗
January 13, 2025
Via
Benzinga
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics
↗
November 12, 2024
Via
Benzinga
Discover the most active stocks in Friday's session.
↗
December 19, 2025
Let's have a look at what is happening on the US markets on Friday. Below you can find the most active stocks in today's session.
Via
Chartmill
Which stocks are moving on Friday?
↗
December 19, 2025
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Via
Chartmill
Which stocks are gapping on Friday?
↗
December 19, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
↗
November 12, 2024
Via
Benzinga
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
↗
November 12, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights
↗
November 07, 2024
Via
Benzinga
Discover the top movers in Friday's pre-market session.
↗
December 19, 2025
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms
↗
December 03, 2025
One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.
Via
The Motley Fool
Topics
Regulatory Compliance
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?
↗
December 03, 2025
PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.
Via
The Motley Fool
Topics
Regulatory Compliance
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?
↗
December 03, 2025
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?
Via
The Motley Fool
Topics
Regulatory Compliance
Amicus Therapeutics Inc (NASDAQ:FOLD) Q3 2025 Earnings: A Landmark Quarter with Strong Profitability Beat
↗
November 04, 2025
Amicus Therapeutics (FOLD) beats Q3 2025 earnings estimates with strong revenue growth and a major milestone in profitability, driving positive market momentum.
Via
Chartmill
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
↗
September 18, 2025
Via
Benzinga
Amicus (FOLD) Q2 Revenue Jumps 22%
↗
August 01, 2025
Via
The Motley Fool
Topics
Intellectual Property
Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading
↗
July 31, 2025
Amicus Therapeutics (FOLD) beats Q2 2025 revenue and EPS estimates, driven by strong growth in Galafold and Pompe disease therapies, sparking a 2.77% pre-market rally.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 01, 2025
Via
Benzinga
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
↗
December 13, 2024
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.
Via
Benzinga
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
↗
October 17, 2024
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
